Recombinant SARS-COV-2 Spike S1 (D614G) Protein
Product Specifications
Background
The SARS-CoV-2 spike (S) protein is the target of vaccine design efforts to end the COVID-19 pandemic. Despite a low mutation rate, isolates with the D614G substitution in the S protein appeared early during the pandemic, and are now the dominant form worldwide. Here, we analyze the D614G mutation in the context of a soluble S ectodomain construct.
Swiss Prot
QHD43416.1
Expression System
HEK293
Conjugation
Unconjugated
Tag
His-Avi
Source
Recombinant SARS-COV-2 Spike S1 (D614G) Protein protein is expressed in HEK293 with His-Avi. It contains the amino acid sequence of Gln14-Arg683.
Applications
WB, ELISA, HPLC
Endotoxin
Less than 1EU per ug by the LAL method.
Purity
> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC
Buffer
Lyophilized from 0.22um filtered solution in 20mM PB (pH 7.4) . 5% trehalose is added as a protectant before lyophilization.
Storage Conditions
The product should be stored at -70°C or -20°C.
Species
SARS-CoV-2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1399573-01 0.02 mg (E-Coli)
Recombinant Bacillus anthracis Uracil phosphoribosyltransferase (upp)
Ask
View Details 
MBS1399573-02 0.1 mg (E-Coli)
Recombinant Bacillus anthracis Uracil phosphoribosyltransferase (upp)
Ask
View Details MBS1399573-03 0.02 mg (Yeast)
Recombinant Bacillus anthracis Uracil phosphoribosyltransferase (upp)
Ask
View Details 
MBS1399573-04 0.1 mg (Yeast)
Recombinant Bacillus anthracis Uracil phosphoribosyltransferase (upp)
Ask
View Details MBS1399573-05 0.02 mg (Baculovirus)
Recombinant Bacillus anthracis Uracil phosphoribosyltransferase (upp)
Ask
View Details MBS1399573-06 0.02 mg (Mammalian-Cell)
Recombinant Bacillus anthracis Uracil phosphoribosyltransferase (upp)
Ask
View Details